IMMUNOGEN INC

Form 4

November 29, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

See Instruction

1. Name and Address of Reporting Person * SAYARE MITCHEL

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

(Check all applicable)

Chief Executive Officer

Issuer

(Last)

(First) (Middle) IMMUNOGEN INC [IMGN]

(Street)

C/O IMMUNOGEN, INC., 128

3. Date of Earliest Transaction

(Month/Day/Year)

X Director

10% Owner _ Other (specify

11/27/2007

X_ Officer (give title below)

SIDNEY STREET

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

CAMBRIDGE, MA 02139

(City)	(State)	(Zip) Tabl	le I - Non-I	Derivative	Securi	ities Acqu	ired, Disposed of	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securit on(A) or Di (Instr. 3,	sposed	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(D)	Price	(Instr. 3 and 4)		
Common Stock	11/27/2007		M	11,500	A	\$ 0.844	537,778	D	
Common Stock	11/27/2007		S	1,700	D	\$ 4.84	536,078	D	
Common Stock	11/27/2007		S	1,300	D	\$ 4.82	534,778	D	
Common Stock	11/27/2007		S	1,100	D	\$ 4.81	533,678	D	
Common Stock	11/27/2007		S	1,261	D	\$ 4.8	532,417	D	

Edgar Filing: IMMUNOGEN INC - Form 4

Common Stock	11/27/2007	S	2,039	D	\$ 4.83	530,378	D
Common Stock	11/27/2007	S	800	D	\$ 4.79	529,578	D
Common Stock	11/27/2007	S	300	D	\$ 4.78	529,278	D
Common Stock	11/27/2007	S	1,800	D	\$ 4.86	527,478	D
Common Stock	11/27/2007	S	300	D	\$ 4.85	527,178	D
Common Stock	11/27/2007	S	200	D	\$ 4.88	526,978	D
Common Stock	11/27/2007	S	400	D	\$ 4.87	526,578	D
Common Stock	11/27/2007	S	300	D	\$ 4.89	526,278	D
Common Stock	11/28/2007	M	29,300	A	\$ 0.844	555,578	D
Common Stock	11/28/2007	S	2,000	D	\$ 4.845	553,578	D
Common Stock	11/28/2007	S	800	D	\$ 4.92	552,778	D
Common Stock	11/28/2007	S	244	D	\$ 4.88	552,534	D
Common Stock	11/28/2007	S	100	D	\$ 4.79	552,434	D
Common Stock	11/28/2007	S	128	D	\$ 4.77	552,306	D
Common Stock	11/28/2007	S	372	D	\$ 4.78	551,934	D
Common Stock	11/28/2007	S	4,051	D	\$ 4.8	547,883	D
Common Stock	11/28/2007	S	200	D	\$ 4.87	547,683	D
Common Stock	11/28/2007	S	1,100	D	\$ 4.81	546,583	D
Common Stock	11/28/2007	S	609	D	\$ 4.86	545,974	D
Common Stock	11/28/2007	S	3,907	D	\$ 4.84	542,067	D
	11/28/2007	S	121	D	\$ 4.9	541,946	D

Edgar Filing: IMMUNOGEN INC - Form 4

Common Stock						
Common Stock	11/28/2007	S	3,786	D	\$ 4.85 538,160	D
Common Stock	11/28/2007	S	9,682	D	\$ 4.83 528,478	D
Common Stock	11/28/2007	S	2,200	D	\$ 4.82 526,278	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Am Underlying Sec (Instr. 3 and 4)
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title O
Non-qualified stock option (right to buy)	\$ 0.844	11/27/2007		M	11,500	12/31/1998(1)	12/31/2007	Common Stock
Non-qualified stock option (right to buy)	\$ 0.844	11/28/2007		M	29,300	12/31/1998(1)	12/31/2007	Common Stock

Reporting Owners

Reporting Owner Name / Address	Kelationships						
	Director	10% Owner	Officer	Other			
SAYARE MITCHEL C/O IMMUNOGEN, INC. 128 SIDNEY STREET CAMBRIDGE, MA 02139	X		Chief Executive Officer				

Reporting Owners 3

Signatures

/s/ Daniel M. Junius, attorney in fact 11/29/2007

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercisable as to 76,389 shares commencing on December 31, 1998, 76,389 shares commencing on December 31, 1999, and 76,388 shares commencing on December 31, 2000.
- (2) Field N/A to this transaction but was completed to allow for electronic filing only.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 4